Improvements in Quality of Life, Health Utility, Cost, and Return to Work for Lymphoma Patients After Chimeric Antigen Receptor T Cell Therapy in a Real-World Setting
Dr. Kelvin Chan
March 1 2025 | Project value $235,000 | 1 partner | $200,000 from BioCanRx
March 1 2025 | Project value $235,000 | 1 partner | $200,000 from BioCanRx
Eligible cancers: Blood cancers
Keywords: Chimeric antigen receptor T cells, quality of life, health utilities, out-of-pocket costs, time costs, cost-effectiveness analysis, real-world evidence
Keywords: Chimeric antigen receptor T cells, quality of life, health utilities, out-of-pocket costs, time costs, cost-effectiveness analysis, real-world evidence
Excelerating Tumor-Infiltrating Lymphocytes (TIL) as a Treatment for Melanoma (TIL-ME)
Dr. Dean Fergusson
November 1, 2024 | Project value $215,594 | 1 partner | $215,594 from BioCanRx
November 1, 2024 | Project value $215,594 | 1 partner | $215,594 from BioCanRx
Eligible cancers: Melanoma
Keywords: Tumor, immunotherapy, lymphocytes, melanoma, Excelerator, systematic review, clinical trial protocol, economic analysis
Keywords: Tumor, immunotherapy, lymphocytes, melanoma, Excelerator, systematic review, clinical trial protocol, economic analysis
LabPartners: Co-Creation of Best Practice Training Resources for Preclinical Patient Engagement in Cancer-Immunotherapy Research
Dr. Manoj Lalu
April 1, 2025 | Project value $250,000 | 1 partner | $200,000 from BioCanRx
April 1, 2025 | Project value $250,000 | 1 partner | $200,000 from BioCanRx
Eligible cancers: various
Keywords: Patient engagement in research, preclinical research, preclinical patient engagement, knowledge translation, user-centred design
Keywords: Patient engagement in research, preclinical research, preclinical patient engagement, knowledge translation, user-centred design
LabPartners: Co-Creation of Best Practice Training Resources for Preclinical Patient Understanding the Economic Value of Decentralized CAR-T Therapies for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
Dr. Kednapa Thavorn
April 1, 2025 | Project value $199,978 | 1 partner | $199,978 from BioCanRx
April 1, 2025 | Project value $199,978 | 1 partner | $199,978 from BioCanRx
Eligible cancers: Blood cancers
Keywords: Chimeric antigen receptor T-cell therapy, point-of-care decentralized manufacturing, acute lymphoblastic leukemia, health technology assessment, patient preferences, discrete choice experiment, economic evaluation
Keywords: Chimeric antigen receptor T-cell therapy, point-of-care decentralized manufacturing, acute lymphoblastic leukemia, health technology assessment, patient preferences, discrete choice experiment, economic evaluation
Excelerating tumor-infiltrating lymphocytes (TIL) as a treatment for melanoma (TIL-ME)
Dean Fergusson & Manoj Lalu, Ottawa Hospital Research Institute
Approved October 2024 | $215,594 from BioCanRx
Approved October 2024 | $215,594 from BioCanRx
Eligible cancers: Melanoma
Keywords: Tumor, Immunotherapy, Lymphocytes, Melanoma, Excelerator, Systematic reviw, Clinical trial protocol, Economic analysis
Making Patient Partnerships A Reality in Very Early Phase Clinical Trials (MARVEL): Development of a Patient Engagement Platform
Dr. Manoj Lalu, Ottawa Hospital Research Institute
Approved October 1, 2020 | Project value $583,950 | 4 partner | $361,490 from BioCanRx
Approved October 1, 2020 | Project value $583,950 | 4 partner | $361,490 from BioCanRx
Identifying Effect Modifiers of CAR T-Cell Therapeutic Efficacy
Dr. Dean Fergusson, Ottawa Hospital Research Institute
Approved July 1, 2020 | Project value $190,000 | 5 partner | $100,000 from BioCanRx
Approved July 1, 2020 | Project value $190,000 | 5 partner | $100,000 from BioCanRx
Assessing the Real-World Clinical and Economic Outcomes of Emerging Innovative Technologies in Oncology: The Cases of Biosimilars and CAR T-cells
Dr. Kelvin Chan, Sunnybrook Research Institute
Approved April 1, 2019 | Project value $297,217 | 3 partner | $100,000 from BioCanRx
Approved April 1, 2019 | Project value $297,217 | 3 partner | $100,000 from BioCanRx
Using real-world data and iterative economic evaluation to prioritize resource allocation for care and research in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Dr. Kednapa Thavorn, Ottawa Hospital Research Institute
Approved April 1, 2019 | Project value $284,955 | 4 partner | $100,000 from BioCanRx
Approved April 1, 2019 | Project value $284,955 | 4 partner | $100,000 from BioCanRx
Developing System-level Policy Model for regenerative medicine and cell therapy in Oncology
Dr. William WL Wong, University of Waterloo School of Pharmacy
Approved April 23, 2018 | Project value $100,000 | 1 partner | $100,000 from BioCanRx
Approved April 23, 2018 | Project value $100,000 | 1 partner | $100,000 from BioCanRx
Getting better Outcomes with Chimeric Antigen Receptor T-cell therapy (GO–CART): A BioCanRx Research Excelerator to Safely and Effectively Translate CAR-T Cell Therapy for Hematological Malignancies
Dr. Manoj Lalu, The Ottawa Hospital Research Institute, University of Ottawa
Approved January 17, 2016 | Project value $414,441 | 6 partners | $364,441 from BioCanRx
Approved January 17, 2016 | Project value $414,441 | 6 partners | $364,441 from BioCanRx
Translational Cancer Immunotherapeutics: Improving the Design, Analysis, and Reporting of Preclinical Studies
Dr. Dean Fergusson, The Ottawa Hospital Research Institute, University of Ottawa
Approved January 17, 2016 | Project value $196,093
Approved January 17, 2016 | Project value $196,093
TOWARDS RATIONAL DESIGN OF POLICIES AND PRACTICES TO ENABLE CLINICAL TRANSLATION OF NOVEL CANCER BIOTHERAPEUTICS IN CANADA
Dr. Tania Bubela, Simon Fraser University
Approved January 5, 2016 | Project value $346,386 | 7 partners | $346,386 from BioCanRx
Approved January 5, 2016 | Project value $346,386 | 7 partners | $346,386 from BioCanRx
IMPROVING THE QUALITY OF JUDGEMENT IN CANCER THERAPEUTICS DEVELOPMENT
Dr. Jonathan Kimmelman, McGill University
Approved January 5, 2016 | Project value $534,846 | 1 partner | $534,846 from BioCanRx
Approved January 5, 2016 | Project value $534,846 | 1 partner | $534,846 from BioCanRx
